PSTV logo

PSTV
Plus Therapeutics Inc

22,255
Mkt Cap
$71.15M
Volume
12,640.00
52W High
$2.31
52W Low
$0.1634
PE Ratio
-0.27
PSTV Fundamentals
Price
$0.5177
Prev Close
$0.543
Open
$0.5473
50D MA
$0.5652
Beta
1.20
Avg. Volume
14.72M
EPS (Annual)
-$2.34
P/B
13.48
Rev/Employee
$277,333.33
Loading...
Loading...
News
all
press releases
Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of -100.00% and -36.79%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
More News
News Placeholder
United Therapeutics (UTHR) Beats Q3 Earnings Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of +3.92% and -2.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...
PR Newswire·20d ago
News Placeholder
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
Zacks·20d ago
News Placeholder
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Zacks·21d ago
News Placeholder
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
Plus (PSTV) delivered earnings and revenue surprises of +88.89% and -18.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +47.44% and +116.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Plus (PSTV) Upgraded to Buy: Here's Why
Zacks·5mo ago
News Placeholder
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
Zacks·5mo ago

Latest PSTV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.